What are the indications, techniques, and differences of trans‑arterial chemoembolisation (TACE), trans‑arterial embolisation (TAE), trans‑arterial radio‑embolisation (TARE), and other locoregional therapies for hepatocellular carcinoma in a patient who is not a surgical candidate, has preserved liver function (Child‑Pugh A‑B), and no extra‑hepatic disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Locoregional Therapies for HCC: TACE, TAE, TARE, and Other Procedures

For non-surgical HCC candidates with preserved liver function (Child-Pugh A-B) and no extrahepatic disease, conventional TACE (cTACE) is the first-line locoregional therapy, performed using selective/superselective techniques through tumor-feeding arteries to maximize antitumor activity while minimizing hepatic damage. 1

Primary Indication and Technique for TACE

cTACE is specifically recommended for HCC patients with good performance status, without major vascular invasion or extrahepatic spread, who are ineligible for hepatic resection, liver transplantation, or local ablation therapies (A1 evidence). 1

Technical Execution

  • Selective/superselective catheterization of tumor-feeding arteries is mandatory to maximize efficacy and minimize liver damage 1
  • The procedure combines chemotherapy delivery with arterial embolization
  • Drug-eluting bead TACE (DEB-TACE) produces similar clinical outcomes to cTACE in tumors ≥3 cm and can be considered as an alternative (A2 evidence) 1

Special Scenario: Portal Vein Invasion

In HCC with portal vein invasion, cTACE alone (B2) or cTACE combined with external beam radiation therapy (B1) can be considered when tumors are intrahepatic and liver function is well-preserved 1, 2

Transarterial Embolization (TAE)

TAE (bland embolization without chemotherapy) has equivalent efficacy to TACE based on randomized controlled trial evidence 3, 4. The meta-analysis by 3 found no statistically significant difference in overall survival (p=0.36) or progression-free survival (p=0.81) between TAE and TACE, with comparable complication profiles.

When to Consider TAE

  • Patients who cannot tolerate chemotherapy agents
  • Similar survival outcomes with potentially fewer post-procedural adverse effects
  • Works through ischemic tumor necrosis alone

Transarterial Radioembolization (TARE)

TARE results in better quality of life and lower occurrence of post-embolization syndrome compared to cTACE; it can be considered an alternative when remnant liver function is expected to be sufficient after treatment (B2 evidence). 1, 2

Key Advantages of TARE

  • Better quality of life compared to TACE 1
  • Lower post-embolization syndrome rates 1
  • Can be safely used in portal vein thrombosis, unlike TACE 5
  • Particularly beneficial for large tumors (>6 cm) 5

Technical Considerations

  • Uses yttrium-90 microspheres (most common) or holmium-166
  • Requires adequate remnant liver function assessment pre-procedure
  • Dosimetry planning with macroaggregated albumin or scout beads 6

TACE Refractoriness: When to Switch Therapies

A switch to other treatments should be considered when developing one or more of the following after two or more TACE sessions within 6 months: 1, 2

  1. Absence of objective response (no complete or partial response)
  2. New appearance of vascular invasion
  3. New appearance of extrahepatic spread

This is critical—continuing TACE beyond refractoriness worsens outcomes and delays potentially effective alternatives.

Other Locoregional Therapies

Radiofrequency Ablation (RFA) and Microwave Ablation (MWA)

  • For tumors 3-5 cm not amenable to resection: Combined TACE + RFA or MWA increases survival compared to ablation alone (A2 evidence) 1
  • RFA alone is appropriate for single tumors ≤3 cm 1
  • MWA and cryoablation produce comparable outcomes to RFA 1

External Beam Radiation Therapy (EBRT)

EBRT is recommended when patients are unsuitable for resection, transplantation, local ablation, or TACE (C1 evidence). 1

Requirements for EBRT

  • Liver function: Child-Pugh class A or B7
  • Volume constraint: ≥40% of total liver volume must receive ≤30 Gy 1, 2
  • Can be combined with TACE for incomplete responses (B2) 1
  • Effective for portal vein invasion (B2) 1
  • Excellent for symptom palliation (B1) 1

Hepatic Arterial Infusion Chemotherapy (HAIC)

HAIC demonstrates superior outcomes compared to TACE with pooled hazard ratios of 0.57 for PFS and 0.58 for OS (both P<0.001) 7. Consider for:

  • Multiple nodules
  • Vascular invasion
  • Patients not eligible for resection, transplantation, or standard TACE 8

Treatment Algorithm by Clinical Scenario

Single HCC ≤3 cm

  1. First choice: RFA or resection
  2. Alternative: TACE if ablation not feasible
  3. Recent real-world evidence shows TACE with appropriate follow-up achieves similar survival to upfront ablation 9

HCC 3-5 cm, Not Resectable

Combined TACE + RFA/MWA (A2 evidence) 1

Multiple Tumors, No Vascular Invasion, Good Performance Status

  1. First-line: cTACE or DEB-TACE
  2. Alternative: TARE (especially if concerns about liver function or quality of life)

HCC with Portal Vein Invasion

  1. cTACE + EBRT (B1 evidence) 1
  2. cTACE alone (B2 evidence) 1
  3. TARE (safe option unlike TACE alone) 5
  4. HAIC (superior to TACE) 7

Large Tumors (>6 cm)

TARE preferred over TACE 5

Critical Pitfalls to Avoid

  1. Do not continue TACE indefinitely—assess for refractoriness after 2 sessions within 6 months 1, 2
  2. Avoid TACE in main portal vein thrombosis without combining with EBRT or considering TARE instead
  3. Do not use non-selective TACE—always perform selective/superselective catheterization 1
  4. Ensure adequate liver function assessment before TARE—insufficient remnant function leads to liver failure
  5. For EBRT, strictly adhere to volume constraints—>60% liver receiving >30 Gy risks radiation-induced liver disease 1

Comparative Efficacy Hierarchy

Based on the 2024 meta-analysis of 11,576 patients 7, locoregional therapies are not equivalent:

Best outcomes: Surgery-based approaches > RT-based regimens > HAIC > Ablation > TACE/TAE/TARE (embolization-based)

  • RT vs TACE: HR 0.35 for both PFS and OS (P<0.001 and P=0.04) 7
  • HAIC vs TACE: HR 0.57 for PFS, 0.58 for OS (both P<0.001) 7

This hierarchy should inform treatment selection when multiple options are technically feasible, always prioritizing morbidity and mortality outcomes over procedural convenience.

References

Related Questions

What is the Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma and the recommended treatment for each stage?
What does the presence of waxy casts in the urine indicate and how should it be evaluated and managed?
Is testing plasma vitamin C (ascorbic acid) levels clinically useful?
Can salbutamol be used in patients with asthma and bronchitis?
Does Tylenol (acetaminophen) contain any pork-derived ingredients?
In a patient on irbesartan 300 mg daily and amlodipine 5 mg daily, who discontinued hydrochlorothiazide due to hyponatremia (serum sodium 134 mmol/L) and has persistently elevated blood pressure, can the amlodipine dose be increased?
Should I take amlodipine 7.5 mg or 10 mg daily for hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.